Reporting for the family-office world.

Come Join the Family Office Networks’ Webinar Series featuring Asalyxa Bio. Asalyxa Bio’s elegant technology platform enables targeted delivery of therapeutic compounds directly to neutrophils, a key immune cell with relevance to various acute diseases/conditions including COVID-19. This platform is ideal for a variety of diseases where treatments are limited or do not exist.

Background on Company Novel scientific insights to unlock the full potential of B cell therapeutics Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020 Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation for AT-1965 Collaborative team with leadership across all biotech disciplines; premier scientific advisors and leading entrepreneur backers Financing underway to fund AT-1965 clinical initiation and development What you will learn from this webinar How a B cell activation approach differs from other cancer immunotherapy approaches How clinical data drives value creation in cancer immunotherapy How AT-1965 is poised to lead the next frontier in cancer immunotherapy How investment in Akamara will diversify your cancer immunotherapy portfolio Hemptown USA has generated $17.6 million in revenue for 2019 and closed $23M in funding through 2 capital raises. What you will learn from this webinar: About hemp-derived cannabinoids and how Hemptown USA became an established and experienced operator in this emerging industry. The hemp value chain, and Hemptown USA’s diversified revenue approach. What is CBG and why it is the next big cannabinoid. Why Hemptown USA’s production platform and M&A strategy present a unique opportunity for investors.

Join the Family Office Networks Webinar Series Featuring Hemptown USA. Eric Gripentrog, CEO will discuss hemp derived cannabinoids, including CBD and CBG, and the platform that Hemptown USA has built for industry consolidation and integration. Hemptown is a leader in cultivation with a Fortune 500 management team, including leadership from Kellogg and Intel. It is one of the largest producers of CBG globally. Hemptown USA has generated $17.6 million in revenue for 2019 and closed $23M in funding through 2 capital raises. What you will learn from this webinar: About hemp-derived cannabinoids and how Hemptown USA became an established and experienced operator in this emerging industry. The hemp value chain, and Hemptown USA’s diversified revenue approach. What is CBG and why it is the next big cannabinoid. Why Hemptown USA’s production platform and M&A strategy present a unique opportunity for investors.